KABRADG
Kabra Drugs financials
- Market cap
- ₹59 Cr
Quarterly results
Q1 FY27: revenue up 546.4%, net profit up 524.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7 | 20 | 30 | 35 | 46 +546% |
| EBITDA | -0 | -1 | -0 | -1 | 2 +610% | 2 +558% | 1 +658% | 3 +637% |
| Net profit | -0 | -1 | 0 | -0 | 2 +560% | 3 +576% | 1 +172% | 2 +524% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −0.1% 1Y
1Y: ₹20.16 on 9 Sept 2025 → ₹20.14. High ₹34.67 (16 Feb 2026), low ₹15.97 (3 Oct 2025).
Financials, as filed
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹0 Cr | ₹0 Cr | ₹93 Cr |
| Operating profit | ₹-1 Cr | ₹-2 Cr | ₹5 Cr |
| Operating margin | — | — | 5.7% |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net profit | ₹-1 Cr | ₹-1 Cr | ₹5 Cr |
| Net margin | — | — | 5.4% |
| Cash from operations | ₹0 Cr | ₹-5 Cr | ₹-9 Cr |
| Free cash flow | ₹0 Cr | ₹-5 Cr | ₹-10 Cr |
| ROCE | -43.0% | -8.0% | 21.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹24 Cr | ₹24 Cr |
| Reserves | ₹-5 Cr | ₹-5 Cr | ₹-5 Cr | ₹-3 Cr | ₹2 Cr | ₹6 Cr |
| Borrowings | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹0 Cr | ₹1 Cr |
| Other liabilities | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹2 Cr | ₹28 Cr | ₹56 Cr |
| Total liabilities | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹5 Cr | ₹55 Cr | ₹86 Cr |
| Fixed assets | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr |
| Other assets | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹5 Cr | ₹53 Cr | ₹85 Cr |
| Total assets | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹5 Cr | ₹55 Cr | ₹86 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
The ownership split has held steady since Jun 2025. The shareholder count grew 30% to 9,680.
- Public
- 100.0%
Since Jun 2025
- Public −0.01 pp
How it drifted, 12 quarters
Ownership split by quarter, oldest first. Sep '23: Public 100.0%.Dec '23: Public 100.0%.Mar '24: Public 100.0%.Jun '24: Public 100.0%.Sep '24: Public 100.0%.Dec '24: Public 100.0%.Mar '25: Public 100.0%.Jun '25: Public 100.0%.Sep '25: Public 100.0%.Dec '25: Public 100.0%.Mar '26: Public 100.0%.Jun '26: Public 100.0%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Bosco Armando Menezes newly disclosed 1.05% held
- Shiva Kumar Adepu newly disclosed 1.05% held
- Rathna Pathengay newly disclosed 1.01% held
- Adusumilli Sai Raghava Pratap +0.21 pp 1.36% held
The same filing shows 2 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Kabra Drugs Ltd above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Kuniamuthur Nanjappan Anand | 2.78% | unchanged |
| Somisetty Malathi Latha | 2.22% | unchanged |
| Somisetty Giridhar Gupta | 2.12% | unchanged |
| Veeramreddy Vijay Kumar Reddy | 1.94% | −1.35 pp |
| Chandraprakash Jamnalal Kabra | 1.69% | unchanged |
| Priyam Sachdeva | 1.42% | unchanged |
| Adusumilli Sai Raghava Pratap | 1.36% | +0.21 pp |
| Narendra Babu Veerla | 1.26% | unchanged |
| Akilandeswari Selvamurthy | 1.23% | unchanged |
| Priyam Samir Shah | 1.16% | −1.58 pp |
| Akansha Gupta | 1.06% | unchanged |
| Neha Sagar Shah | 1.05% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Kabra Drugs Ltd
Guides on how to read this kind of business and the numbers that matter.